HKSE - Delayed Quote • HKD
Sino Biopharmaceutical Limited (1177.HK)
At close: 4:08 PM GMT+8
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
28,863,711.000
28,780,412.000
26,861,356.000
23,647,224.000
Cost of Revenue
6,092,416.000
5,795,510.000
5,332,095.000
5,182,320.000
Gross Profit
22,771,295.000
22,984,902.000
21,529,261.000
18,464,904.000
Operating Expense
11,686,591.000
12,389,024.000
12,541,759.000
11,422,834.000
Operating Income
11,084,704.000
10,595,878.000
8,987,502.000
7,042,070.000
Net Non Operating Interest Income Expense
-306,231.000
-237,617.000
-146,560.000
-129,365.000
Pretax Income
5,248,159.000
5,778,604.000
18,572,673.000
5,013,044.000
Tax Provision
729,338.000
775,986.000
1,957,880.000
672,377.000
Net Income Common Stockholders
1,881,317.000
2,543,570.000
14,608,412.000
2,771,086.000
Average Dilution Earnings
--
-232,370.000
-482,511.000
--
Diluted NI Available to Com Stockholders
1,809,884.000
2,311,200.000
14,125,901.000
2,771,086.000
Basic EPS
0.10
0.14
0.78
0.15
Diluted EPS
0.10
0.12
0.73
0.15
Basic Average Shares
18,574,918.508
18,622,248.991
18,768,649.757
18,800,284.155
Diluted Average Shares
18,737,912.346
19,017,201.976
19,282,955.090
18,800,284.155
Total Expenses
17,779,007.000
18,184,534.000
17,873,854.000
16,605,154.000
Net Income from Continuing & Discontinued Operation
1,881,317.000
2,543,570.000
14,608,412.000
2,771,086.000
Normalized Income
2,072,233.986
2,952,745.362
14,860,393.598
2,383,158.635
Interest Income
267,693.000
201,441.000
162,057.000
194,003.000
Interest Expense
573,924.000
439,058.000
308,617.000
323,368.000
Net Interest Income
-306,231.000
-237,617.000
-146,560.000
-129,365.000
EBIT
5,822,083.000
6,217,662.000
18,881,290.000
5,336,412.000
EBITDA
5,822,083.000
7,264,646.000
19,873,846.000
6,991,248.000
Reconciled Cost of Revenue
6,092,416.000
5,795,510.000
5,332,095.000
5,182,320.000
Reconciled Depreciation
--
1,046,984.000
992,556.000
1,654,836.000
Net Income from Continuing Operation Net Minority Interest
1,881,317.000
2,543,570.000
14,608,412.000
2,771,086.000
Total Unusual Items Excluding Goodwill
-221,731.000
-472,645.000
-281,675.000
448,018.000
Total Unusual Items
-221,731.000
-472,645.000
-281,675.000
448,018.000
Normalized EBITDA
6,043,814.000
7,737,291.000
20,155,521.000
6,543,230.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-30,814.014
-63,469.638
-29,693.402
60,090.635
12/31/2020 - 5/12/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2269.HK WuXi Biologics (Cayman) Inc.
12.900
-0.62%
1801.HK Innovent Biologics, Inc.
38.150
+5.53%
1548.HK Genscript Biotech Corporation
10.840
-1.28%
1877.HK Shanghai Junshi Biosciences Co., Ltd.
9.730
+0.83%
9688.HK Zai Lab Limited
12.380
+2.48%
9939.HK Kintor Pharmaceutical Limited
0.950
-1.04%
2197.HK Clover Biopharmaceuticals, Ltd.
0.320
-3.03%
2142.HK HBM Holdings Limited
1.120
-2.61%
2126.HK JW (Cayman) Therapeutics Co. Ltd
1.720
-1.71%
9926.HK Akeso, Inc.
47.450
+1.06%